ArticleDermatology and therapy2012
Rituximab in the treatment of pemphigus vulgaris.
Article in Dermatology and therapy, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 67 citations in OpenAlex.
- CD4+ T Cells Predict Relapse in Pemphigus Vulgaris Treated With Rituximab: A Retrospective Study.Oral diseases · 2026Article
- Impact of rituximab on IgG and IgM levels in patients with autoimmune bullous diseases: a cohort study.Archives of dermatological research · 2025Article
- Clinical correlation of anti-desmoglein antibody dynamics in pemphigus treated with rituximab.Frontiers in immunology · 2025Article
- Review
- Cytokine profiling reveals HLA-linked Th2 and Th17 driven immune activation in pemphigus vulgaris patients and genetically susceptible healthy controls.Frontiers in immunology · 2024Article
- Rituximab in Pemphigus Vulgaris: A Review of Monoclonal Antibody Therapy in Dermatology.Cureus · 2023Review
- Anterior scleritis in pemphigus vulgaris: A rare ocular manifestation.Indian journal of ophthalmology · 2022Article
- Real world evidence: Patients with refractory pemphigus treated with Rituximab.Metabolism open · 2021Article
- Modified Rheumatoid Arthritis Protocol for Rituximab in Pemphigus: A Retrospective Case Series.The Journal of clinical and aesthetic dermatology · 2020Article
- Emerging treatment options for the management of pemphigus vulgaris.Therapeutics and clinical risk management · 2018Review
- Rituximab: A Magic Bullet for Pemphigus.Journal of clinical and diagnostic research : JCDR · 2017Article
- Cytokine Indexes in Pemphigus Vulgaris: Perception of Its Immunpathogenesis and Hopes for Non-Steroidal Treatment.Iranian journal of pharmaceutical research : IJPR · 2017Article
- Management of pemphigus vulgaris: challenges and solutions.Clinical, cosmetic and investigational dermatology · 2015Review
- Biologics in dermatology: an integrated review.Indian journal of dermatology · 2014Review
- Plakophilin-1 protects keratinocytes from pemphigus vulgaris IgG by forming calcium-independent desmosomes.The Journal of investigative dermatology · 2014Article
- p38 MAPK Signaling in Pemphigus: Implications for Skin Autoimmunity.Autoimmune diseases · 2013Article
- Comparison of the Clinical Efficacy of Rituximab Infusion and Dexamethasone-Cyclophosphamide Pulse Therapy and Their Effect on Serum Th1, Th2, and Th17 Cytokines in Pemphigus Vulgaris-A Prospective, Nonrandomized, Comparative Pilot Study.Indian dermatology online journalArticle
- Shifting Focus in the Therapeutics of Immunobullous Disease.Indian journal of dermatologyArticle
- Follow-up Data of Rituximab as Adjuvant Therapy in Pemphigus.Indian journal of dermatologyArticle
- Low Dose Vs Conventional Rituximab Regimen in Pemphigus Vulgaris - A Retrospective Single Centre Comparative Analysis to Assess the Clinical Efficacy and Cost-Effectiveness.Indian dermatology online journalArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRituximab is increasingly used in patients with pemphigus vulgaris (PV) who are nonresponders to conventional therapy.
methodsA PubMed search was conducted using the words pemphigus vulgaris and rituximab therapy from papers published between 2000 and 2012. Two protocols were used. In the lymphoma protocol, patients received four weekly infusions of rituximab (dose 375 mg/m(2)). The rheumatoid arthritis (RA) protocol consisted of two infusions of 1,000 mg each 15 days apart. The variables recorded from each study included clinical remission off or on therapy, relapse rate, incidence of serious adverse events, concomitant therapies, duration of follow-up, and when available, levels of B cells and autoantibodies.
resultsForty-two studies were found, which reported 272 patients; 180 were treated by the lymphoma protocol and 92 by the RA protocol. Both protocols were effective in treating recalcitrant PV. The lymphoma protocol had a lower response rate, relapse rate and serious infections, but higher mortality, and there were nonresponders. The RA protocol produced a higher response rate, relapse rate, number of infections, but lower mortality rate, and lacked nonresponders. The cumulative follow-up for patients treated with the lymphoma protocol was 15.44 months (range 1-41) and 21.04 months (range 8.35-29) for the RA protocol. A major concern in both protocols was the high infection rates, some of which were fatal. A different protocol using a combination of rituximab with intravenous immunoglobulin in a defined manner with a definitive endpoint, used in a limited cohort of patients, showed promising results.
conclusionNeither protocol produced a sustained clinical remission and both required continued systemic therapy. Before initiation of treatment, physicians should have a specific goal and endpoint and be aware of its potential side effects and lack of information on its long-term effects. Patients should be carefully monitored during and after therapy.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.